FIG. 4.
Basal expression and inhibition of ppERK1/2 and ppMKK1/2 by CI-1040 or U0126 in thyroid cancer cells. C643, TPC1, BCPAP, SW1736, and K1 cells were grown in RPMI supplemented with (A) 10% FBS or (B) 2% FBS, and treated with or without the MKK1/2 inhibitors, U0126 (3 μM) or CI-1040 (0.5 μM), for the indicated times. Whole cell extracts (30 μg) were separated on 10% PAGE-SDS gels, transferred to Immobilon-P, and probed with the indicated antibodies.